

Alexa Fluor® 647 anti-mouse/human CD45R/B220 Antibody

Catalog# / Size	103229 / 25 µg 103226 / 100 µg
Clone	RA3-6B2
Regulatory Status	RUO
Other Names	B220
Isotype	Rat IgG2a, κ
Description	CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL- <i>Fas^{lpr}</i> and MRL- <i>Fas^{gld}</i> mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details

Verified Reactivity	Mouse, Human
Reported Reactivity	Cat
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Abelson murine leukemia virus-induced pre-B tumor cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 647 under optimal conditions.
Concentration	0.5 mg/mL
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested IHC-F, 3D IHC - Verified SB - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per million cells in 100 µL volume. For immunohistochemistry on frozen tissue sections, a concentration range of 2.5 - 5.0 µg/mL is suggested. For immunofluorescence microscopy, a concentration range of 1.25 - 10 µg/mL is recommended. It is recommended that the reagent be titrated for optimal performance for each application. * Alexa Fluor® 647 has a maximum emission of 668 nm when it is excited at 633nm / 635nm. Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation. View full statement regarding label licenses
Excitation Laser	Red Laser (633 nm)
Application Notes	Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ , <i>in vitro</i> and <i>in vivo</i> modulation of B cell responses ²⁻⁴ , immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections ^{5,6} , and spatial

biology (IBEX)^{14,15}.

Additional Product Notes

Iterative Bleaching Extended multi-plexity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Coffman RL. 1982. *Immunol. Rev.* 69:5. (IP)
2. George A, *et al.* 1994. *J. Immunol.* 152:1014. (Activ)
3. Asensi V, *et al.* 1989. *Immunology* 68:204. (Activ)
4. Domiati-Saad R, *et al.* 1993. *J. Immunol.* 151:5936. (Activ)
5. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
6. Monteith CE, *et al.* 1996. *Can. J. Vet. Res.* 60:193. (IHC)
7. Shih FF, *et al.* 2006. *J. Immunol.* 176:3438. (FC)
8. Chang C L-T, *et al.* 2007. *J. Immunol.* 178:6984.
9. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
10. Lang GL, *et al.* 2008. *Blood* 111:2158. [PubMed](#)
11. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
12. del Rio ML, *et al.* 2011. *Transpl. Int.* 24:501. (FC) [PubMed](#)
13. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)
14. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
15. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Cabañero D, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
2. Wang Y, *et al.* 2021. *Cancer Res.* 81:174. [PubMed](#)
3. Kim EH, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
4. Jong RM, *et al.* 2022. *J Immunol.* 208:407. [PubMed](#)
5. Delvecchio FR, *et al.* 2021. *Cell Mol Gastroenterol Hepatol.* 12:1543. [PubMed](#)
6. Kang S, *et al.* 2016. *J Immunol.* 196: 196 - 206. [PubMed](#)
7. Hu HJ, *et al.* 2020. *Cell Death Dis.* 1.168055556. [PubMed](#)
8. Barry KC, *et al.* 2018. *Nat Med.* 24:1178. [PubMed](#)
9. Farsakoglu Y *et al.* 2019. *Cell reports.* 26(9):2307-2315 . [PubMed](#)
10. Chou YJ, *et al.* 2020. *Sci Rep.* 10:8422. [PubMed](#)
11. Brownlie R, *et al.* 2008. *J Exp Med.* 205:883. [PubMed](#)
12. Bangs DJ, *et al.* 2022. *Cell Rep.* 38:110266. [PubMed](#)
13. Neubert K, *et al.* 2014. *J Immunol.* 192:5830. [PubMed](#)
14. Webster HC, *et al.* 2020. *J Immunol Methods.* 112702:477. [PubMed](#)
15. LaFleur MW, *et al.* 2019. *Nat Immunol.* 20:1335. [PubMed](#)
16. Folgosa L, *et al.* 2013. *J Immunol.* 191:5951. [PubMed](#)
17. Sarapulov AV, *et al.* 2020. *Front Immunol.* 11:599. [PubMed](#)
18. Dai B, *et al.* 2022. *Theranostics.* 12:7603. [PubMed](#)
19. Medgyesi D, *et al.* 2014. *J Exp Med.* 211:427. [PubMed](#)
20. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
21. Lin JR *et al.* 2018. *eLife.* 7 pii: e31657. [PubMed](#)
22. Fallet B, *et al.* 2020. *Cell Rep.* 30:1013. [PubMed](#)
23. Liu D *et al.* 2019. *Immunity.* 51(1):64-76 . [PubMed](#)
24. Cheng HW, *et al.* 2019. *Nat Commun.* 10:1739. [PubMed](#)
25. Daniel CJ, *et al.* 2022. *Mol Cancer Res.* 20:1151. [PubMed](#)
26. Yang J, *et al.* 2019. *FASEB J.* 33:12780. [PubMed](#)
27. Lian J, *et al.* 2020. *Cell Reports.* 31(8):107679. [PubMed](#)
28. Dobosz E, *et al.* 2021. *Dis Model Mech.* :14. [PubMed](#)
29. Chauveau A, *et al.* 2020. *Immunity.* 52:794. [PubMed](#)
30. Vogel AB, *et al.* 2021. *Nature.* 592:283. [PubMed](#)
31. Magri G *et al.* 2017. *Immunity.* 47(1):118-134 . [PubMed](#)
32. Tsai F, *et al.* 2017. *J Exp Med.* 214:3753. [PubMed](#)
33. Simula L *et al.* 2018. *Cell reports.* 25(11):3059-3073 . [PubMed](#)
34. Hermetet F, *et al.* 2019. *Nat Commun.* 10:523. [PubMed](#)
35. Beura LK, *et al.* 2018. *Immunity.* 48:327. [PubMed](#)
36. Ramakrishnan SK, *et al.* 2019. *Nat Commun.* 10:660. [PubMed](#)
37. Chen C, *et al.* 2021. *J Virol.* 95:e0082921. [PubMed](#)
38. Cheng HW, *et al.* 2022. *Nat Commun.* 13:2027. [PubMed](#)
39. Gil-Cruz C, *et al.* 2012. *Proc Natl Acad Sci U S A.* 109:1233. [PubMed](#)
40. Fleig S, *et al.* 2022. *Nat Commun.* 13:2022. [PubMed](#)
41. Hoechst B, *et al.* 2016. *J Immunol.* 195:1517-1523. [PubMed](#)
42. Cao A, *et al.* 2018. *Nat Commun.* 9:3288. [PubMed](#)
43. Prados A, Kollias G, Koliarakis V 2016. *Sci Rep.* 6: 33027. [PubMed](#)
44. Smith LK, *et al.* 2021. *Elife.* 10:. [PubMed](#)
45. Harumiya S, *et al.* 2013. *Arch Biochem Biophys.* 533:18. [PubMed](#)
46. Dammeijer F, *et al.* 2020. *Cancer Cell.* 38(5):685-700.e8. [PubMed](#)
47. Campisi L, *et al.* 2016. *Nat Immunol.* 10.1038/ni.3512. [PubMed](#)
48. Yoshikawa S, *et al.* 2016. *Sci Rep.* 6:18738. [PubMed](#)

RRID

AB_492875 (BioLegend Cat. No. 103229)
AB_389330 (BioLegend Cat. No. 103226)

Antigen Details

Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	B cells, T cell subset, NK cell subset
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4
Cell Type	B cells, NK cells, T cells
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family	CD Molecules
Antigen References	<ol style="list-style-type: none">1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.
Gene ID	19264 5788

Related Protocols

[Immunohistochemistry Protocol for Frozen Sections](#)


[Cell Surface Flow Cytometry Staining Protocol](#)

[Immunocytochemistry Staining Protocol](#)


Other Formats

Alexa Fluor® 594 anti-mouse/human CD45R/B220, APC anti-mouse/human CD45R/B220, Biotin anti-mouse/human CD45R/B220, FITC anti-mouse/human CD45R/B220, PE anti-mouse/human CD45R/B220, PE/Cyanine5 anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220, PE/Cyanine7 anti-mouse/human CD45R/B220, APC/Cyanine7 anti-mouse/human CD45R/B220, Alexa Fluor® 488 anti-mouse/human CD45R/B220, Alexa Fluor® 647 anti-mouse/human CD45R/B220, Pacific Blue™ anti-mouse/human CD45R/B220, Alexa Fluor® 700 anti-mouse/human CD45R/B220, PerCP anti-mouse/human CD45R/B220, PerCP/Cyanine5.5 anti-mouse/human CD45R/B220, Brilliant Violet 421™ anti-mouse/human CD45R/B220, Brilliant Violet 570™ anti-mouse/human CD45R/B220, Brilliant Violet 650™ anti-mouse/human CD45R/B220, Brilliant Violet 605™ anti-mouse/human CD45R/B220, Brilliant Violet 785™ anti-mouse/human CD45R/B220, Brilliant Violet 510™ anti-mouse/human CD45R/B220, Purified anti-mouse/human CD45R/B220 (Maxpar® Ready), Brilliant Violet 711™ anti-mouse/human CD45R/B220, PE/Dazzle™ 594 anti-mouse/human CD45R/B220, APC/Fire™ 750 anti-mouse/human CD45R/B220, Brilliant Violet 750™ anti-mouse/human CD45R/B220, TotalSeq™-A0103 anti-mouse/human CD45R/B220, Spark Blue™ 550 anti-mouse/human CD45R/B220, Spark NIR™ 685 anti-mouse/human CD45R/B220, TotalSeq™-B0103 anti-mouse/human CD45R/B220, Ultra-LEAF™ Purified anti-mouse/human CD45R/B220, TotalSeq™-C0103 anti-mouse/human CD45R/B220, PE/Fire™ 640 anti-mouse/human CD45R/B220, APC/Fire™ 810 anti-mouse/human CD45R/B220, PE/Fire™ 700 anti-mouse/human CD45R/B220, Spark Violet™ 538 anti-mouse/human CD45R/B220, Spark YG™ 581 anti-mouse/human CD45R/B220, Spark YG™ 570 anti-mouse/human CD45R/B220, PE/Fire™ 810 anti-mouse/human CD45R/B220, Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody, Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody, Spark Red™ 718 anti-mouse/human CD45R/B220


Product Data



C57BL/6 mouse splenocytes stained with RA3-6B2 Alexa Fluor® 647



C57BL/6 mouse frozen lymph node sections were fixed with 4% paraformaldehyde (PFA) for 10 minutes at room temperature and blocked with 5% FBS plus 5% rat serum for 1 hour at room temperature. Then the section was stained with 5 µg/mL of CD4 (clone GK1.5) Alexa Fluor® 594 (red), 5 µg/mL of B220 (clone RA3-6B2) Alexa Fluor® 647 (green) overnight at 4°C. The image was captured by 10X objective.



Formalin-fixed, 300 micron-thick mouse spleen section was blocked, permeabilized and stained overnight with CD3 (clone 17A2) Alexa Fluor® 488 (red), CD21/35 (CR2/CR1)(clone 7E9) Alexa Fluor® 594 (green), and CD45R/B220 (clone RA3-6B2) Alexa Fluor® 647 (blue) all at 5 µg/mL, optically cleared, then analyzed at 215 µm imaging depth on a confocal microscope.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587